Compare GAME & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAME | MIRA |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 43.7M |
| IPO Year | 2024 | 2023 |
| Metric | GAME | MIRA |
|---|---|---|
| Price | $0.44 | $0.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 116.2K |
| Earning Date | 04-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $44,999,302.00 | N/A |
| Revenue This Year | $87.12 | N/A |
| Revenue Next Year | $21.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.24 | $0.90 |
| 52 Week High | $2.87 | $2.45 |
| Indicator | GAME | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 51.87 | 43.88 |
| Support Level | $0.44 | $0.91 |
| Resistance Level | $0.49 | $1.22 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 51.74 | 13.16 |
GameSquare Holdings Inc is a vertically integrated digital media, entertainment, and technology company focused on gaming and youth culture audiences. The company operates through four reportable segments: Owned and Operated IP, Agency, SaaS and managed services, and Yield. It provides services including influencer marketing, esports talent management, creative production, merchandise and consumer products, live streaming analytics, and digital media solutions through its various brands and platforms. It generates the majority of its revenue from the Agency segment.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.